title: Fluconazole resistance in cryptococcal disease: emerging or intrinsic?
abstract: With the widespread use of long-term fluconazole prophylaxis and suppressive treatment, the potential development of fluconazole resistance poses a threat to the management of cryptococcal disease. Interpretive breakpoints for the in vitro antifungal susceptibility testing of C. neoformans have not been established and it is unclear whether the fluconazole minimum inhibitory concentration (MIC) is clinically relevant. To gain insight into the management of patients with cryptococcosis who fail fluconazole therapy, we conducted a PubMed literature search for cases of fluconazole-resistant cryptococcosis reported from 1991 to 2011. A total of 20 such cases were identified in which most patients had AIDS and 30% had never had prior exposure to fluconazole. Fluconazole failure in patients with cryptococcal disease cannot be fully attributed to emerging resistance of the etiologic agent and heteroresistance is a potential alternative mechanism. There is a need to refine the definition of fluconazole-resistant cryptococcosis and additional studies of such patients will improve treatment strategies and outcomes.
authors.affiliation: Department of Infectious Diseases, Mater Health Services, Raymond Terrace, South Brisbane, Australia.
authors.forename: Jenny Wan Sai
authors.initials: JW
authors.lastname: Cheong
authors.forename: Joe
authors.initials: J
authors.lastname: McCormack
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000494:pharmacology*; D002648:Child; D003453:Cryptococcosis / Q000382:microbiology*; D003454:Cryptococcus / Q000187:drug effects* / Q000302:isolation & purification; D025141:Drug Resistance, Fungal; D005260:Female; D015725:Fluconazole / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole